Bristol Myers Squibb Co (BMY): Total Liabilities
$71.53B
As of 2025-12-31
$65.31B
As of 2026-06-30
+2.9%
3-year compound annual growth
-2.4%
5-year compound annual growth
+15.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.53B | -6.1% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $76.22B | +16.1% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $65.67B | 0.0% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $65.70B | -10.4% | 2024-02-13, Balance as of period end |
| 2021-12-31 | $73.31B | -9.0% | 2023-02-14, Balance as of period end |
| 2020-12-31 | $80.60B | +3.0% | 2022-02-09, Balance as of period end |
| 2019-12-31 | $78.25B | +275.1% | 2021-02-10, Balance as of period end |
| 2018-12-31 | $20.86B | -3.9% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $21.70B | +25.0% | 2019-02-25, Balance as of period end |
| 2016-12-31 | $17.36B | +0.2% | 2018-02-13, Balance as of period end |
| 2015-12-31 | $17.32B | -7.7% | 2017-02-21, Balance as of period end |
| 2014-12-31 | $18.77B | -19.7% | 2016-02-12, Balance as of period end |
| 2013-12-31 | $23.36B | +4.9% | 2015-02-13, Balance as of period end |
| 2012-12-31 | $22.26B | +30.1% | 2014-02-14, Balance as of period end |
| 2011-12-31 | $17.10B | +10.8% | 2013-02-15, Balance as of period end |
| 2010-12-31 | $15.44B | -4.8% | 2012-02-17, Balance as of period end |
| 2009-12-31 | $16.22B | -6.1% | 2011-02-18, Balance as of period end |
| 2008-12-31 | $17.28B | n/a | 2010-02-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $32.83B | -2.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $9.30B | +10.7% |
| Viatris Inc (VTRS) | 2025-12-31 | $22.48B | -1.7% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $6.98B | +13.9% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $25.99B | -3.2% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $12.14B | +28.2% |
Compare BMY, PFE, JNJ, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗